Fig. 2From: Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the USReasons for adjuvant therapy selection. a Reasons for not prescribing adjuvant therapy – overall and by substage. b Reasons for prescribing Anti-PD1 – overall and by substage. * P-value < 0.05. Abbreviations: LDH, lactate dehydrogenaseBack to article page